Carrier Global Slides to 453rd in Volume Amid Mixed Institutional Bets as Insiders Cut Holdings
On August 8, 2025, Carrier GlobalCARR-- (CARR) fell 0.50% to a volume of $0.22 billion, ranking 453rd in daily trading activity. Analysts have issued a "Moderate Buy" consensus rating based on 17 Wall Street evaluations, with 10 "Buy" and 7 "Hold" recommendations. The average 12-month price target of $84.47 implies a 27.89% upside from its current price of $66.05, though volatility remains a concern given its beta of 1.25.
Institutional investors have adjusted stakes in CARRCARR--, with Vanguard Group reducing its position by 2.5% to 10.84% ownership. Corporate insiders, including Director Maximilian Viessmann, sold over 4 million shares, reflecting a 7.28% reduction in ownership. This selling pressure contrasts with recent institutional buying by Brown Advisory and UBSUBS--, which increased holdings by 82.6% and 15.6%, respectively, signaling mixed confidence in the stock.
Carrier’s Q2 earnings report showed $0.92 per share, exceeding estimates by $0.02, while revenue reached $6.11 billion, slightly above expectations. The company declared a $0.225 quarterly dividend, maintaining a payout ratio of 19.61%. Despite these positives, analysts have lowered some price targets, with BarclaysBCS-- reducing its target to $82.00 from $84.00, and insider selling has raised short-term uncertainty.
Backtest data highlights the effectiveness of a high-volume trading strategy: purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to 2025, outperforming the benchmark by 137.53%. This underscores the role of liquidity concentration in short-term performance, particularly for volatile stocks like CARR, which traded at the 453rd highest volume on August 8.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet